Publication:
Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.

cris.virtual.author-orcid0000-0001-7512-513X
cris.virtual.author-orcid0000-0002-9404-7736
cris.virtualsource.author-orcid9afdf9b4-257a-4736-90ba-96d18a782972
cris.virtualsource.author-orcid86929eee-8f06-473c-9d09-2b6d7b04c082
cris.virtualsource.author-orcid8f95a220-083e-49cf-b70c-791e63056989
cris.virtualsource.author-orcid5772bb1f-51a9-4cd5-b763-e6c548f75535
cris.virtualsource.author-orcid547a1198-2574-4601-aa8a-5a3b147c870e
cris.virtualsource.author-orcid5b02b156-9f93-421d-bb36-a588ac9faa13
cris.virtualsource.author-orcidd6aac6e7-756f-4c96-934a-890456825dd7
cris.virtualsource.author-orcid89351f1b-c3b3-4ff0-af2f-033f39da3188
cris.virtualsource.author-orcide3d9151a-ebe0-4fa6-9f4e-8afa41cb8127
cris.virtualsource.author-orcide85f3902-6c21-4fe3-bda2-c9126ffc8e84
cris.virtualsource.author-orcid51cae653-8b4a-40cb-801b-42fa96a2f797
cris.virtualsource.author-orcidfe07c5e4-6205-4094-aebe-374a3866a26e
datacite.rightsopen.access
dc.contributor.authorHaas, Quentin
dc.contributor.authorMarkov, Nikita
dc.contributor.authorMürner, Lukas Dominic
dc.contributor.authorRubino, Viviana
dc.contributor.authorBenjak, Andrej
dc.contributor.authorHaubitz, Monika
dc.contributor.authorBärlocher, Gabriela Maria
dc.contributor.authorNg, Kiu Yan Charlotte
dc.contributor.authorMünz, Christian
dc.contributor.authorRiether, Carsten
dc.contributor.authorOchsenbein, Adrian
dc.contributor.authorSimon, Hans-Uwe
dc.contributor.authorvon Gunten, Stephan
dc.date.accessioned2024-10-11T17:22:14Z
dc.date.available2024-10-11T17:22:14Z
dc.date.issued2022
dc.description.abstractWhile inhibitory Siglec receptors are known to regulate myeloid cells, less is known about their expression and function in lymphocytes subsets. Here we identified Siglec-7 as a glyco-immune checkpoint expressed on non-exhausted effector memory CD8+ T cells that exhibit high functional and metabolic capacities. Seahorse analysis revealed higher basal respiration and glycolysis levels of Siglec-7+ CD8+ T cells in steady state, and particularly upon activation. Siglec-7 polarization into the T cell immune synapse was dependent on sialoglycan interactions in trans and prevented actin polarization and effective T cell responses. Siglec-7 ligands were found to be expressed on both leukemic stem cells and acute myeloid leukemia (AML) cells suggesting the occurrence of glyco-immune checkpoints for Siglec-7+ CD8+ T cells, which were found in patients' peripheral blood and bone marrow. Our findings project Siglec-7 as a glyco-immune checkpoint and therapeutic target for T cell-driven disorders and cancer.
dc.description.sponsorshipInstitut für Pharmakologie
dc.description.sponsorshipDepartment for BioMedical Research (DBMR)
dc.description.sponsorshipUniversitätsklinik für Medizinische Onkologie
dc.description.sponsorshipDepartment for BioMedical Research, Forschungsgruppe Tumor-Immunologie
dc.identifier.doi10.48350/173646
dc.identifier.pmid36211376
dc.identifier.publisherDOI10.3389/fimmu.2022.996746
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/88008
dc.language.isoen
dc.publisherFrontiers Research Foundation
dc.relation.ispartofFrontiers in immunology
dc.relation.issn1664-3224
dc.relation.organizationDCD5A442BD11E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BD18E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C2CBE17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C3DBE17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C448E17DE0405C82790C4DE2
dc.relation.organizationFE9070E90049439CAFD7E6B2FE6653E3
dc.relation.organization5EBDFFD4994748B4B44FD17D5E463CFB
dc.relation.schoolDCD5A442C27BE17DE0405C82790C4DE2
dc.subjectCD8+ T cells Siglec-7 acute myeloid leukemia hypersialylation immune checkpoint sialoglycans tumor immunity and immunotherapy
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleSiglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.startPage996746
oaire.citation.volume13
oairecerif.author.affiliationInstitut für Pharmakologie
oairecerif.author.affiliationInstitut für Pharmakologie
oairecerif.author.affiliationInstitut für Pharmakologie
oairecerif.author.affiliationDepartment for BioMedical Research, Forschungsgruppe Tumor-Immunologie
oairecerif.author.affiliationDepartment for BioMedical Research (DBMR)
oairecerif.author.affiliationDepartment for BioMedical Research (DBMR)
oairecerif.author.affiliationDepartment for BioMedical Research (DBMR)
oairecerif.author.affiliationDepartment for BioMedical Research (DBMR)
oairecerif.author.affiliationUniversitätsklinik für Medizinische Onkologie
oairecerif.author.affiliationUniversitätsklinik für Medizinische Onkologie
oairecerif.author.affiliationInstitut für Pharmakologie
oairecerif.author.affiliationInstitut für Pharmakologie
oairecerif.author.affiliation2Universitätsklinik für Medizinische Onkologie
oairecerif.author.affiliation2Department for BioMedical Research, Forschungsgruppe Hämatologie (Erwachsene)
oairecerif.author.affiliation2Department for BioMedical Research, Forschungsgruppe Hämatologie (Erwachsene)
oairecerif.author.affiliation2Department for BioMedical Research, Forschungsgruppe Tumor-Immunologie
oairecerif.author.affiliation2Department for BioMedical Research, Forschungsgruppe Tumor-Immunologie
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2022-10-11 08:50:34
unibe.description.ispublishedpub
unibe.eprints.legacyId173646
unibe.journal.abbrevTitleFront Immunol
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
fimmu-13-996746.pdf
Size:
7.8 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections